Relative utility of 1-h Oral Glucose Tolerance Test as a measure of abnormal glucose homeostasis

Diabetes Research and Clinical Practice

Volumn 93, Issue 2, 2011, Pages 268-275

  Joshipura, K J ^a,b   Andriankaja, M O ^a   Hu, F B ^b   Ritchie, C S ^a,c  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

1 h OGTT; 2 h OGTT; Abnormal glucose homeostasis; Glucose abnormalities; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; RISK FACTOR; SENSITIVITY ANALYSIS; SMOKING HABIT; WAIST CIRCUMFERENCE;

ADIPOSITY; ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TIME FACTORS; WAIST CIRCUMFERENCE;

EID: 80051554802     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.05.035     Document Type: Article

References (27)

1. Abdul-Ghani M.A., Abdul-Ghani T., Ali N., Defronzo R.A. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 2008, 31(August (8)):1650-1655.
2. Abdul-Ghani M.A., Lyssenko V., Tuomi T., DeFronzo R.A., Groop L. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care 2009, 32(February (2)):281-286.
3. Executive Summary: Standards of Medical Care in Diabetes-2010. Diabetes Care 2010 Jan;33 (Suppl.1): 4-10.
4. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26(November (11)):3160-3167.
5. WHO/IDF Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF Consultant 2006, World Health Organization, Geneva.
6. Kilpatrick E.S., Bloomgarden Z.T., Zimmet P.Z. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes: response to the International Expert Committee. Diabetes Care 2009, 32(December (12)). e60; e159; author reply.
7. Bartnik M., Ryden L., Malmberg K., Ohrvik J., Pyorala K., Standl E., et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the euro heart survey on diabetes and the heart. Heart 2007 Jan, 93(January (1)):72-77.
8. Meigs J.B., Nathan D.M., D'Agostino R.B., Wilson P.W. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham offspring study. Diabetes Care 2002 Oct, 25(10):1845-1850.
9. Selvin E., Steffes M.W., Zhu H., Matsushita K., Wagenknecht L., Pankow J., et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362(March (9)):800-811.
10. Edelstein S.L., Knowler W.C., Bain R.P., Andres R., Barrett-Connor E.L., Dowse G.K., et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 1997, 46(April (4)):701-710.
11. Buhling K.J., Winkel T., Wolf C., Kurzidim B., Mahmoudi M., Wohlfarth K., et al. Optimal timing for postprandial glucose measurement in pregnant women with diabetes and a non-diabetic pregnant population evaluated by the Continuous Glucose Monitoring System (CGMS). J Perinat Med 2005, 33(2):125-131.
12. Retnakaran R., Qi Y., Sermer M., Connelly P.W., Zinman B., Hanley A.J. Isolated hyperglycemia at 1 hour on oral glucose tolerance test in pregnancy resembles gestational diabetes mellitus in predicting postpartum metabolic dysfunction. Diabetes Care 2008, 31(July (7)):1275-1281.
13. Jovanovic L. Rationale of prevention and treatment of postprandial glucose-mediated toxicity. Endocrinologist 1999, 9:87-92.
14. Warnick G.R., Knopp R.H., Fitzpatrick V., Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 1990, 36(January (1)):15-19.
15. CDC. Third national health and nutrition examination survey anthropometric procedures video: Centers for Disease Control and Prevention. National Center for Health Statistics.
16. Perloff D., Grim C., Flack J., Frohlich E.D., Hill M., McDonald M., et al. Human blood pressure determination by sphygmomanometry. Circulation 1993, 88(November (5 Pt 1)):2460-2470.
17. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006, 21(January (1)):1-6.
18. Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106(December (25)):3143-3421.
19. Pekkanen J., Linn S., Heiss G., Suchindran C.M., Leon A., Rifkind B.M., et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990, 322(June (24)):1700-1707.
20. Madeira I.R., Carvalho C.N., Gazolla F.M., de Matos H.J., Borges M.A., Bordallo M.A. Cut-off point for Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index established from Receiver Operating Characteristic (ROC) curve in the detection of metabolic syndrome in overweight pre-pubertal children. Arq Bras Endocrinol Metabol 2008, 52(December (9)):1466-1473.
21. Kesavalu L., Chandrasekar B., Ebersole J.L. In vivo induction of proinflammatory cytokines in mouse tissue by Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans. Oral Microbiol Immunol 2002, 17(June (3)):177-180.
22. Gallagher D., Heymsfield S.B., Heo M., Jebb S.A., Murgatroyd P.R., Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000, 72(September (3)):694-701.
23. Bardini G., Dicembrini I., Cresci B., Rotella C.M. Inflammation markers and metabolic characteristics of subjects with 1-h plasma glucose levels. Diabetes Care 2010, 33(February (2)):411-413.
24. Meisinger C., Wolke G., Brasche S., Strube G., Heinrich J. Postload plasma glucose and 30-year mortality among nondiabetic middle-aged men from the general population: the ERFORT study. Ann Epidemiol 2006, 16(July (7)):534-539.
25. Abdul-Ghani M.A., Stern M.P., Lyssenko V., Tuomi T., Groop L., Defronzo R.A. Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose. Diabetes Care 2010, 33(March (3)):557-561.
26. Manco M., Panunzi S., Macfarlane D.P., Golay A., Melander O., Konrad T., et al. One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. Diabetes Care 2010, 33(September (9)):2090-2097.
27. Barrett-Connor E. The oral glucose tolerance test, revisited. Eur Heart J 2002, 23(August (16)):1229-1231.